Changes in MMP-2 and -9 activity and MMP-8 reactivity after amphotericin B induced synovitis and treatment with bufexamac

Journal of Veterinary Medicine Series A: Physiology Pathology Clinical Medicine

Volumn 53, Issue 6, 2006, Pages 311-318

  Marttinen, P H ^a   Raulo, S M ^a   Suominen, M M ^a   Tulamo, R M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIINFLAMMATORY AGENT; BUFEXAMAC; GELATINASE A; GELATINASE B; NEUTROPHIL COLLAGENASE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMISTRY; ENZYMOLOGY; FEMALE; HORSE; HORSE DISEASE; MALE; METABOLISM; RANDOMIZATION; SYNOVIAL FLUID; SYNOVITIS; TREATMENT OUTCOME;

AMPHOTERICIN B; ANIMALS; ANTI-INFLAMMATORY AGENTS; BUFEXAMAC; FEMALE; HORSE DISEASES; HORSES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; RANDOM ALLOCATION; SYNOVIAL FLUID; SYNOVITIS; TREATMENT OUTCOME;

EQUIDAE; EQUUS CABALLUS;

EID: 33746327149     PISSN: 0931184X     EISSN: 14390442     Source Type: Journal    
DOI: 10.1111/j.1439-0442.2006.00837.x     Document Type: Article

References (55)

1. AAEP, 1991: AAEP Guide for Judging of Equestrian Events, Definition and Classification of Lameness, 4th edn. American Association of Equine Practitioners Office, Lexington, KY, pp. 19.
2. Atkinson, J. J., and R. M. Senior, 2003: Matrix metalloproteinase-9 in lung remodeling. Am. J. Respir. Cell Mol. Biol. 28, 12-24.
3. Billinghurst, R. C., E. M. Buxton, M. G. Edwards, M. S. McGraw, C. W. McIlwraith, 2001: Use of an antineoepitope antibody for identification of type II collagen degradation in equine articular cartilage. Am. J. Vet. Res. 62, 1031-1039.
4. Birkedal-Hansen, H., W. G. I. Moore, M. K. Bodden, L. J. Windsor, B. Birkedal-Hansen, A. DeCarlo, J. A. Engler, 1993: Matrix metalloproteinases: a review. Crit. Rev. Oral. Biol. Med. 4, 197-250.
5. van den Boom, R., P. A. J. Brama, G. H. Kiers, J. DeGroot, A. Barneveld, and R. R. van Weeren, 2004: The influence of repeated arthrocentesis and exercise on matrix metalloproteinase and tumour necrosis factor a activities in normal equine joints. Equine Vet. J. 36, 155-159.
6. van den Boom, R., M. R. van der Harst, H. Brommer, P. A. J. Brama, A. Barneveld, P. R. van Weeren, and J. DeGroot, 2005a: Relationship between synovial fluid levels of glycosaminoglycans, hydroxyproline and general MMP activity and the presence and severity of articular cartilage change on the proximal articular surface of P1. Equine Vet. J. 37, 19-25.
7. 2 and glycosaminoglycans in healthy equine joints. Equine Vet. J. 37, 250-256.
8. Brama, P. A. J., R. van den Boom, J. DeGroot, G. H. Kiers, P. R. van Weeren, 2004: Collagenase-1 (MMP-1) activity in equine synovial fluid: influence of age, joint pathology, exercise and repeated arthrocentesis. Equine Vet. J. 36, 34-40.
9. Brandt, K. D., and H. J. Mankin, 1986: Workshop on the etiopathogenesis of osteoarthritis. J. Rheum. 13, 1126-1160.
10. Burrage, P. S., K. S. Mix, and C. E. Brinckerhoff, 2006: Matrix metalloproteinases: role in arthritis. Front. Biosci. 11, 529-543.
11. Catterall, J. B., and T. E. Cawston, 2003: Drugs in development: bisphosphonates and metalloproteinase inhibitors. Arthritis Res. Ther. 5, 12-24.
12. 2-dependent mechanism in human chondrocytes. Exp. Mol. Med. 36, 226-232.
13. Chu, S. C., S. F. Yang, K. H. Lue, Y. S. Hsieh, T. Y. Hsiao, and K. H. Lu, 2004: The clinical significance of gelatinase B in gouty arthritis of the knee. Clin. Chim. Acta 339, 77-83.
14. Clegg, P. D., and S. D. Carter, 1999: Matrix metalloproteinase-2 and - 9 are activated in joint diseases. Equine Vet. J. 31, 324-330.
15. Clegg, P. D., R. M. Burke, A. R. Coughlan, C. M. Riggs, and S. D. Carter, 1997a: Characterisation of equine matrix metalloproteinase 2 and 9 and identification of the cellular sources of these enzymes in joints. Equine Vet. J. 29, 335-342.
16. Clegg, P. D., A. R. Coughlan, C. M. Riggs, and S. D. Carter, 1997b: Matrix metalloproteinases 2 and 9 in equine synovial fluids. Equine Vet. J. 29, 343-348.
17. Clegg, P. D., M. D. Jones, and S. D. Carter, 1998: The effect of drugs commonly used in the treatment of equine articular disorders on the activity of equine matrix metalloproteinase-2 and 9. J. Vet. Pharmacol. Ther. 21, 406-413.
18. Flower, R. J., and J. R. Vane, 1974: Inhibition of prostaglandin biosynthesis. Biochem. Pharmacol. 23, 1439-1450.
19. Fridman, R., M. Toth, and D. Pena, 1995: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 55, 2548-2555.
20. Hernandez, J., and D. L. Hawkins, 2001: Training failure among yearling horses. Am. J. Vet. Res. 62, 1418-1422.
21. Ito, A., T. Nose, S. Takahashi, and Y. Mori, 1995: Cyclo-oxygenase inhibitors augment the production of pro-matrix metalloproteinase 9 (progelatinase B) in rabbit articular chondrocytes. FEBS Lett. 360, 75-79.
22. Jones, S. L., and A. Blikslager, 2001: The future of antiinflammatory therapy. Vet. Clin. North Am. Equine Pract. 17, 245-262.
23. Jouglin, M., C. Robert, J. P. Valette, F. Gavard, F. Quintin-Colonna, and J. M. Denoix, 2000: Metalloproteinases and tumor necrosis factor-alpha activities in synovial fluids of horses: correlation with articular cartilage alterations. Vet. Res. 31, 507-515.
24. Kähäri, V. M., and U. Saarialho-Kere, 1999: Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann. Med. 31, 34-45.
25. Kallings, P., 1993: Nonsteroidal anti-inflammatory drugs. Vet. Clin. North Am. Equine Pract. 9, 523-541.
26. Kirker-Head, C. A., V. K. Chandna, R. K. Agarwal, E. A. Morris, A. Tidwell, M. W. O'Callaghan, W. Rand, and M. S. Kumar, 2000: Concentrations of substance P and prostaglandin E2 in synovial fluid of normal and abnormal joints of horses. Am. J. Vet. Res. 61, 714-718.
27. Konttinen, Y. T., S. Halinen, R. Hanemaaijer, T. Sorsa, J. Hietanen, A. Ceponis, J. W. Xu, Manthorpe, R., J. Whittington, A. Larsson, T. Salo, L. Kjeldsen, U. H. Stenman, and A. Z. Eisen, 1998: Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjögren's syndrome. Matrix Biol. 17, 335-347.
28. Koolwijk, P., A. M. Miltenburg, M. G. van Erck, M. Oudshoom, M. J. Niedbala, F. C. Breedveld, and V. W. van Hinsbergh, 1995: Activated gelatinase-B (MMP-9) and urokiase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation. J. Reumatol. 22, 385-393.
29. Kozaci, I. D., D. J. Buttles, and A. P. Hollander, 1997: Degradation of type II collagen but not proteoglycan correlates with matrix metalloproteinase activity in cartilage explant cultures. Arthr. Rheum. 40, 164-174.
30. Malemud, C. J., J. Martel-Pelletier, and J. P. Pelletier, 1987: Degradation of extracellular matrix in osteoarthritis: 4 fundamental questions. J. Rheumatol. 14, 20-22.
31. Martel-Pelletier, J., D. J. Welsch, and J. P. Pelletier, 2001: Metalloproteases and inhibitors in arthritic diseases. Best Pract. Res. Clin. Rheumatol. 15, 805-829.
32. May, S. A., R. E. Hooke, and P. Lees, 1988: The effect of drugs used in the treatment of osteoarthrosis on stromelysin (proteoglycanase) of equine synovial cell origin. Equine Vet. J. Suppl. 6, 28-32.
33. McIlwraith, C. W., 2002: Pathobiology of joints and their reaction to insult and injury. In: Stashak, T. S. (ed.), Adams' Lameness in Horses, pp. 469-479. Lippincott Williams & Wilkins, Baltimore.
34. McIlwraith, C. W., J. F. Fessler, W. E. Blevins, E. H. Page, A. H. Rebar, D. C. Van Sickle, and G. L. Coppoc, 1979: Experimentally induced arthritis of the equine carpus: clinical determinations. Am. J. Vet. Res. 40, 11-20.
35. McQuibban, G. A., G. S. Butler, J. H. Gong, L. Bendall, C. Power, I. Clark-Lewis, and C. M. Overall, 2001: Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J. Biol. Chem. 276, 43503-43508.
36. Mehindate, K., R. al Daccak, J. M. Dayer, B. P. Kennedy, C. Kris, P. Borgeat, P. E. Poubelle, and W. Mourad, 1995: Superantigen-induced collagenase gene expression in human IFN-gamma-treated fibroblast-like synoviocytes involves prostaglandin E2. Evidence for a role of cyclooxygenase-2 and cytosolic phospholipase A2. J. Immunol. 155, 3570-3577.
37. Mifflin, R. C., J. I. Saada, J. F. Di Mari, P. A. Adegboyega, J. D. Valentich, and D. W. Powell, 2002: Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. Am. J. Physiol. Cell Physiol. 282, 824-834.
38. Morris, E. A., B. S. McDonald, A. C. Webb, and L. J. Rosenwasser, 1990: Identification of interleukin-1 in equine osteoarthritic joint effusions. Am. J. Vet. Res. 51, 59-64.
39. Peloso, J. G., J. A. Stick, R. W. Soutas-Little, J. C. Caron, C. E. DeCamp, and D. H. Leach, 1993: Computer-assisted three-dimensional gait analysis of amphotericin-induced carpal lameness in horses. Am. J. Vet. Res. 54, 1535-1543.
40. Raulo, S. M., and P. Maisi, 1998: Gelatinolytic activity in tracheal epithelial lining fluid and in blood from horses with chronic obstructive pulmonary disease. Am. J. Vet. Res. 59, 818-823.
41. Raulo, S. M., T. A. Sorsa, M. T. Kiili, and P. S. Maisi, 2001: Evaluation of collagenase activity, matrix metalloproteinase-8, and matrix metalloproteinase-13 in horses with chronic obstructive pulmonary disease. Am. J. Vet. Res. 62, 1142-1148.
42. Raulo, S. M., T. Sorsa, T. Tervahartiala, T. Latvanen, E. Pirila, J. Hirvonen, and P. Maisi, 2002: Increase in milk metalloproteinase activity and vascular permeability in bovine endotoxin induced and naturally occurring Escherichia coli mastitis. Vet. Immunol. Immunopathol. 85, 137-145.
43. Romanelli, R., S. Mancini, C. Laschinger, C. M. Overall, J. Sodek, and C. A. McCulloch, 1999: Activation of neutrophil collagenase in periodontitis. Infect Immun. 67, 2319-2326.
44. Roncucci, R., G. Lambelin, M. J. Simon, and K. Debast, 1973: In vitro action of bufexamac and selected hydroxamin acids on isolated rat lever lysosomes. Arch. Int. Pharmocodyn. Ther. 203, 348-367.
45. Sadowski, T., and J. Steinmeyer, 2001: Effects of non-steroidal anti-inflammatory drugs and dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes. Osteoarthr. Cartil. 9, 407-415.
46. Shapiro, S. D., and R. M. Senior, 1999: Matrix metalloproteinases. Matrix degradation and more. Am. J. Respir. Cell. Mol. Biol. 20, 1100-1102.
47. Sorsa, T., Y. T. Konttinen, O. Lindy, C. Ritchlin, H. Saari, K. Suomalainen, K. K. Eklund, and S. Santavirta, 1992: Collagenase in synovitis of rheumatoid arthritis. Semin. Arthritis. Rheum. 22, 44-53.
48. Suominen, M. M., R.-M. Tulamo, L. M. Puupponen, and S. M. Sankari, 1999: Effects of intra-articular injections of bufexamac suspension on amphotericin B-induced aseptic arthritis in horses. Am. J. Vet. Res. 60, 1467-1473.
49. Suominen, M. M., R.-M. Tulamo, M. O. Anttila, S. M. Sankari, K. Kiraly, T. Lapvetelainen, and H. J. Helminen, 2001: Effects of intra-articular injections of bufexamac suspension in healthy horses. Am. J. Vet. Res. 62, 1629-1635.
50. Thompson, C. C., P. D. Clegg, and S. D. Carter, 2001: Differential regulation of gelatinases by transforming growth factor beta-1 in normal equine chondrocytes. Osteoarthr. Cartil. 9, 325-331.
51. Trumble, T. N., G. W. Trotter, J. R. Oxford, C. W. McIlwraith, S. Cammarata, J. L. Goodnight, R. C. Billinghurst, and D. D. Frisbie, 2001: Synovial fluid gelatinase concentrations and matrix metalloproteinase and cytokine expression in naturally occurring joint disease in horses. Am. J. Vet. Res. 62, 1467-1477.
52. Van Cauwenberge, H., and P. Frachimont, 1968: Etude experimentale et clinique d'un nouvel anti-inflammatoire non steroidien: ácide butoxyphenylacet hydroxamique (Droxaryl). J. Belge. Rhumatol. Med. Phys. 23, 133-148.
53. Vignon, E., P. Mathieu, P. Louisot, and M. Richard, 1991: In vitro effect of nonsteroidal anti-inflammatory drugs on proteoglycanase and collagenase activity in human osteoarthritic cartilage. Arthr. Rheum. 34, 1332-1335.
54. Visse, R., and H. Nagase, 2003: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827-839.
55. Woessner, J. F., 1994: The family of matrix metalloproteinases. Ann. N. Y. Acad. Sci. 732, 11-21.